Now, let’s discuss🖐key pearls when analyzing CSF🧐for poss infection🦠
1️⃣Consider the source!
Obtained from a…
▶️“Closed”system, ie LP💉?
▶️“Open”system, ie EVD🧠?
⚠️Interpret CSF💦from “open”sys w/caution▶️blood🩸& inflammation🔥from underlying condition are often present
What’s blood🩸got to do with it?🤨
2️⃣RBC contamination🩸in CSF may occur from“traumatic” tap or🩸from SAH w/EVD
In a bloody tap, peripheral blood will mix with CSF sample🧪 ▶️ inaccurate reflection of WBC
🌟Correct WBC for presence of RBCs by using 1:1000 ratio (WBC:RBC) 💡
Unfortunately, this diagnostic dilemma also exists with glucose & protein ⚠️ w/an EVD but no correction formula exists.
3️⃣Any other markers to assess infection if an EVD is present? 🤔
⭐️CSF LACTATE🧪may be a useful adjunct to culture & analysis to assess for 🧠infection🦠
CSF sample from EVD is NEG 🚫but concerned for 🧠infection!?
🔑CSF from EVD = ventricular CSF 🧠 vs. LP = lumbar CSF 🦴 ▶️ samples from sites may yield different results
4️⃣Some lit📚suggests CSF from LP 2x ⬆️sensitivity vs EVD
If suspicion is⬆️but EVD CSF neg, consider LP
And for the 5️⃣th & final pearl from your friendly pharmacist 👩🏻⚕️ 💊
🧫 CSF PCR can be a useful adjunct to detect potential organisms 🦠 & results faster⏰ than traditional gram stain & culture to assist in optimizing antimicrobial therapy 💊 💉 #IDTwitter#NeuroTwitter
What additional pearls do you consider when analyzing CSF 🧠 💦 for suspected infection in the presence of an EVD? 🦠
Last week I had one of my final presentations of the year! With a catchy title😉
Urine for an Update! Updates in the management of metastatic urothelial cancer
Hold your bladders, this is an extensive update! 😂 #oncopharm
Bladder cancer can be divided into two ✌️subtypes: 1) Non-muscle invasive: encompasses in-situ and localized disease➡️5-yr OS >70%
2) Muscle invasive: encompasses regional or metastatic disease➡️5-yr OS dismal especially for metastatic disease 😔
Cisplatin=SOC
50% of pts w are ineligible due to older age👵🏻, poor PS, ⬇️ renal function, ⬇️hearing, neuropathy, heart failure 🫀& other comorbities that ⬆️ risk of ⚠️
Carboplatin yields inferior responses➡️NOT 🙅🏻♀️ an equal alternative due to ⬇️ OS😢➡️pt left w/minimal tx options
What medications 💊 are should be avoided 🛑 or used with caution ⚠️ in patients with Myasthenia Gravis? 🤔
See 👀 the thread 🧵below⤵️ that summarizes an amazing grand rounds presentation by @UKPharmRes PGY1 @AliW_PharmD on key 🔑 medication considerations in MG
1️⃣Antibiotics to avoid or use w/caution🦠 💊
🛑FQs = FDA BBW for ⤴️ risk of MG crisis ➡️ avoid use if possible
⚠️ Macrolides ⤴️ rate of MG crisis (case reports)
⚠️ AG linked to ⤴️ ICU acquired weakness & exacerbate ‼️ MG crisis
📝Risk⬆️ w/neomycin vs. tobramycin & amikacin
Antibiotics considered to be SAFE alternatives to the above include
✅Beta-lactams
✅Tetracyclines
✅Linezolid
✅Bactrim
Ex. In an MG patient who presents 🏥 w/CAP 🫁 ➡️ choose ceftriaxone + doxycycline✅ OVER ceftriaxone + azithromycin🛑
Immune checkpoint inhibitors (ICI) ➡️revolutionized tx 💊 of various malignancies
✅Treatment that offers some pts🙋🏻♀️a chance of cure🤯
Also see a range of unique toxicities⚠️➡️autoimmune in nature
An emerging one of which is nephritis! (Insert a needed kidney emoji)
Pathogenesis of ICI-nephritis is unknown
Some hypothesis exist 🧐
✅stopping the breaks on the immune system results in excessive immune activation➡️ATIN
✅Previous renal insult or concurrent medications that lead to ATIN can accelerate the emergence of renal injury ☢️
I would like to make a few points of clarification for yesterday tweet on Vasopressin for cardiogenic shock.
🔑 point: Vasopressin is not “preferred” nor 1st line in CS but “may be considered” in select cases
Please read further thread 👇🏻👇🏻
It should have stated “may consider” VP as the suggestion of benefit in the JAHA article on CS was based on theoretical benefit and a ☝️ post hoc analysis of the VASST trial which included septic shock patients, notably a VERY different pathophys than CS. pubmed.ncbi.nlm.nih.gov/22518026/
Article did not also mention potential risk of harm from Vasopressin. (fluid retention, lack of inotropic activity, etc) and as @brentnreed pointed out, patients in this study required MORE inotropic support when vasopressin was used
What factors do you have to consider while treating a cancer pt with a malignant pleural effusion and concurrent infection? 🤔
1/ 🚨Cancer pts are at risk for MPE➡️consequence of metastatic involvement of the primary tumor in the pleura💨
💡Lung, breast, and lymphoma are the most common causes💡
Query of the pleural fluid with the use of the Lights criteria will help to determine the etiology (transudative or exudative)
Exudative=malignant OR infection
One of the criteria is a serum protein ratio >0.5
Since both MPE & infectious effusions🦠contain↗️↗️protein
🛑Avoid highly protein bound abx (Ex: daptomycin, ceftriaxone, ertapenem)➡️can get sequestered in the pleural fluid& have↘️systemic distribution & ↘️the ability to treat a bacteremia if present 😳🤯